bluebird bio, Inc. (NASDAQ:BLUE) was upgraded by BidaskClub from a “sell” rating to a “hold” rating in a report issued on Wednesday, August 9th.
Other equities research analysts have also issued reports about the company. Maxim Group raised bluebird bio from a “hold” rating to a “buy” rating and set a $100.00 price target for the company in a research report on Friday, June 2nd. BTIG Research reissued a “buy” rating and issued a $112.00 price target on shares of bluebird bio in a research report on Thursday, June 1st. Standpoint Research started coverage on bluebird bio in a research report on Tuesday, May 30th. They issued a “buy” rating and a $110.00 price target for the company. BMO Capital Markets reissued a “buy” rating and issued a $108.00 price target on shares of bluebird bio in a research report on Tuesday, June 6th. Finally, Janney Montgomery Scott increased their price target on bluebird bio from $81.00 to $125.00 and gave the company a “buy” rating in a research report on Wednesday, June 7th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $100.74.
bluebird bio (BLUE) opened at 92.45 on Wednesday. The company’s 50-day moving average is $96.49 and its 200-day moving average is $91.07. bluebird bio has a 12 month low of $37.05 and a 12 month high of $123.75. The stock’s market capitalization is $4.21 billion.
bluebird bio (NASDAQ:BLUE) last issued its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.66) by $0.07. bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The firm had revenue of $16.70 million for the quarter, compared to analyst estimates of $6.29 million. During the same period in the previous year, the company earned ($1.59) earnings per share. bluebird bio’s revenue for the quarter was up 977.4% compared to the same quarter last year. Equities analysts anticipate that bluebird bio will post ($6.78) earnings per share for the current year.
In other bluebird bio news, insider Philip D. Gregory sold 750 shares of the firm’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $99.00, for a total value of $74,250.00. Following the sale, the insider now owns 31,234 shares of the company’s stock, valued at approximately $3,092,166. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Philip D. Gregory sold 1,500 shares of the firm’s stock in a transaction dated Tuesday, June 6th. The shares were sold at an average price of $99.04, for a total value of $148,560.00. Following the transaction, the insider now directly owns 37,279 shares in the company, valued at $3,692,112.16. The disclosure for this sale can be found here. In the last ninety days, insiders sold 80,106 shares of company stock worth $8,308,358. Insiders own 3.90% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP boosted its position in shares of bluebird bio by 0.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 68,220 shares of the biotechnology company’s stock worth $4,210,000 after buying an additional 540 shares during the period. Macquarie Group Ltd. acquired a new stake in shares of bluebird bio during the fourth quarter worth $703,000. Candriam Luxembourg S.C.A. raised its stake in shares of bluebird bio by 17.5% in the first quarter. Candriam Luxembourg S.C.A. now owns 161,000 shares of the biotechnology company’s stock worth $14,636,000 after buying an additional 24,000 shares in the last quarter. First Mercantile Trust Co. raised its stake in shares of bluebird bio by 14.4% in the first quarter. First Mercantile Trust Co. now owns 2,897 shares of the biotechnology company’s stock worth $263,000 after buying an additional 365 shares in the last quarter. Finally, Strs Ohio raised its stake in shares of bluebird bio by 40.5% in the first quarter. Strs Ohio now owns 5,900 shares of the biotechnology company’s stock worth $536,000 after buying an additional 1,700 shares in the last quarter.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.